Shares of the Botox maker, which is also a target of Actavis
Plc, rose 1.3 pct in premarket trading after the company
also gave a full-year profit forecast that was higher than
analysts' average expectations.

"Today's announced expectations for the third quarter and
updated future outlook further demonstrate that there is a vast
value gap between Valeant's offer and the intrinsic value of
Allergan," Allergan Chief Executive David Pyott said in a
statement.

The company has been trying to fend off an acquisition by
the Canadian drugmaker, while Actavis plans to approach Allergan
about a potential merger, sources told Reuters earlier this
week.

Allergan on Thursday estimated adjusted earnings of
$1.76-$1.78 per share for the quarter ended Sept. 30, higher
than its forecast of $1.44-$1.47, helped by an increase in
market share and product approvals.

The company said it also expects a 14-15 percent increase in
product net sales for the full year.

Analysts on average were expecting a profit of $1.48 per
share, according to Thomson Reuters I/B/E/S.